AMENDMENT UNDER 37 C.F.R. § 1.116 EXPEDITED PROCEDURE GROUP 1631 PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of Docket No: Q71975 Levon ARAKELYAN, et al. Appln. No.: 10/662,345 Group Art Unit: 1631 Confirmation No.: 2068 Examiner: Lori A Clow Filed: September 16, 2003 A METHOD FOR OPTIMIZING THE EFFICACY OF CLINICAL TRIALS DURING For: DRUG DEVELOPMENT SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.116 **MAIL STOP AF** Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 Sir: In response to the Office Action dated June 24, 2009, for which an Amendment Under 37 C.F.R. § 1.116 was filed August 24, 2009, and an Advisory Action was mailed September 10, 2009, please consider the remarks and amendments as follows on the accompanying pages TABLE OF CONTENTS AMENDMENTS TO THE CLAIMS2

REMARKS9